Cancer Vaccines Market

Description

The cancer vaccines market was valued at approximately US$ 7.87 billion in 2024 and is anticipated to grow to US$ 16.86 billion, with a compound annual growth rate (CAGR) of 11.5% throughout the forecast period. Key trends in the cancer vaccines market are expected to include the development of personalized cancer vaccines, an emphasis on combination therapies, and increased investments in research and development for cancer vaccines.

Analysis of the Cancer Vaccines Market

The rising global incidence of cancer is likely to propel the growth of the cancer vaccines market. Cancer remains one of the leading causes of death worldwide and significantly impacts quality of life. If not diagnosed and treated promptly, cancer poses a substantial burden on society. According to a report from the World Health Organization, there were approximately 19,976,499 cancer cases reported in 2022, with projections estimating that this number will rise to 32.6 million by 2045.

This increasing prevalence of cancer across various regions is driving the global demand for vaccines.

Overview of the Cancer Vaccines Market

The global cancer vaccines market is categorized by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Growth in these regions is anticipated due to factors such as the rising prevalence of cancer globally and initiatives by health research organizations and key industry players focused on cancer vaccines. However, the limited availability of commercially viable cancer treatment vaccines and their high costs may hinder market growth to some extent during the forecast period.

Strategic Insights

Drivers and Opportunities in the Cancer Vaccines Market

Global Health Initiatives Supporting Cancer Vaccines

Emerging Markets: Opportunities in the Cancer Vaccines Sector

Developing nations in the Asia-Pacific region are presenting substantial business expansion opportunities for major market players. Many companies are focusing on emerging markets like India and China due to the high number of cancer patients and the growth of medical tourism in these areas. According to the Malaysia Healthcare Travel Council, over 850,000 healthcare travelers visited Malaysia in 2022 for various medical needs. The lower costs of surgeries and the availability of advanced technologies with minimal waiting times are attracting global patients to these developing countries for medical procedures, including cancer screenings. The rising incidence of cancer is creating further opportunities in the market; for example, India recorded approximately 1,413,316 new cancer cases in 2022. Thus, the surge in medical tourism and the increasing prevalence of cancer in emerging markets are providing significant growth prospects for industry players.

Key segments contributing to the analysis of the cancer vaccines market include services and applications.

The market is segmented by technology into dendritic cell cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, and viral vector cancer vaccines. The recombinant cancer vaccines segment held the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period.
By type, the market is divided into preventive cancer vaccines and therapeutic cancer vaccines. The preventive cancer vaccines segment dominated the market in 2023 and is projected to have the highest CAGR in the forecast period.
By indication, the market is categorized into cervical cancer, prostate cancer, and other indications. The cervical cancer segment accounted for the largest market share in 2023 and is expected to register the highest CAGR during the forecast period.
The market is segmented by end-user into pediatrics and adults. The pediatrics segment held the largest market share in 2023 and is anticipated to show the highest CAGR in the forecast period.

Geographical Analysis of the Cancer Vaccines Market

The geographical scope of the cancer vaccines market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South America/South & Central America.

North America, which includes the US, Canada, and Mexico, held a significant share of the global market in 2023. The demand in this region is expected to grow at a notable rate during the forecast period due to factors such as the increasing need for cancer diagnosis and treatment, rising cancer incidence, substantial R&D investments, heightened competition among market players, and government funding for research institutions to develop new therapies.

The Asia Pacific region is the fastest-growing market for cancer vaccines globally, driven by advancements in cancer vaccine development in countries like Japan and China. The large population of cancer patients, an increasing number of research initiatives, growing government support, and a rise in startups and biotech firms in this region are contributing to market growth opportunities.

Scope of the Cancer Vaccines Market Report

Recent Developments in the Cancer Vaccines Market

The cancer vaccines market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the cancer vaccines market:

In December 2023, Oxford University Hospitals initiated a new mRNA cancer vaccine trial for patients with head and neck cancers. (Source: Company Press Release)
In February 2024, Moderna began trials for its cancer vaccine mRNA-4359 at Imperial College Healthcare NHS Trust, aiming to evaluate the safety and potential efficacy of the treatment for melanoma, lung cancer, and other solid tumors. (Source: Company Press Release)

Coverage and Deliverables of the Cancer Vaccines Market Report

The report titled "Cancer Vaccines Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

Market size and forecasts at global, regional, and country levels for all key segments included in the scope
Market dynamics, including drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter's Five Forces and SWOT analysis
Global and regional market analysis highlighting key trends, major players, regulations, and recent developments
Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
In-depth company profiles

Product Code: TIPRE00004595

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Cancer Vaccines Market and By Technology
- 1.3.2 Global Cancer Vaccines Market and By Type
- 1.3.3 Global Cancer Vaccines Market and By Indication
- 1.3.4 Global Cancer Vaccines Market and By End-User
- 1.3.5 Global Cancer Vaccines market and By Geography

2. Cancer Vaccines Market and Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Cancer Vaccines Market and Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America and PEST Analysis
- 4.2.2 Europe and PEST Analysis
- 4.2.3 Asia Pacific and PEST Analysis
- 4.2.4 Middle East and Africa (MEA) and PEST Analysis
- 4.2.5 South and Central America (SCAM) and PEST Analysis
4.3 Expert Opinions

5. Cancer Vaccines Marketand Key Market Dynamics

5.1 Key Market Drivers
- 5.1.1 Increase in Prevalence of Cancer Worldwide
- 5.1.2 Initiatives Taken by Global Health Research Organizations and Key Players for Cancer Vaccines
5.2 Key Market Restraints
- 5.2.1 Less Number of Commercially Available Vaccines for Treatment of Cancer
- 5.2.2 Higher Cost of Cancer Vaccines
5.3 Key Market Opportunities
- 5.3.1 Emerging Markets in Developing Countries
5.4 Future Trends
- 5.4.1 Growing Research and Development Activities
5.5 Impact analysis

6. Cancer Vaccines Market and Global Analysis

6.1 Global Cancer Vaccines Market Revenue Forecast and Analysis
6.2 Global Cancer Vaccines Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Cancer Vaccines Market and By Technology

7.1 Overview
7.2 Cancer Vaccines Market, by Technology, 2024 and 2031 (%)
7.3 Dendritic Cells Cancer Vaccine
- 7.3.1 Overview
- 7.3.2 Dendritic Cells Cancer Vaccines : Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
7.5 Recombinant Cancer Vaccines
- 7.5.1 Overview
- 7.5.2 Recombinant Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
7.6 Antigen Cancer Vaccines
- 7.6.1 Overview
- 7.6.2 Antigen Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
7.7 Whole Cell Cancer Vaccines
- 7.7.1 Overview
- 7.7.2 Whole Cell Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
7.8 Viral Vector Cancer Vaccines
- 7.8.1 Overview
- 7.8.2 Viral Vector Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

8. Cancer Vaccines Market Analysis and By Type

8.1 Overview
8.2 Cancer Vaccines Market Revenue Share, by Type (2024 and 2031)
8.3 Preventive Cancer Vaccines
- 8.3.1 Overview
- 8.3.2 Preventive Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
8.4 Therapeutic Cancer Vaccines
- 8.4.1 Overview
- 8.4.2 Therapeutic Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

9. Cancer Vaccines Market Analysis and By Indication

9.1 Overview
9.2 Cancer Vaccines Market Revenue Share, by Indication (2024 and 2031)
9.3 Cervical Cancer
- 9.3.1 Overview
- 9.3.2 Cervical Cancer: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
9.4 Prostate Cancer
- 9.4.1 Overview
- 9.4.2 Prostate Cancer: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
9.5 Other Indications
- 9.5.1 Overview
- 9.5.2 Other Indications: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

10. Cancer Vaccines Market Analysis and By End Use

10.1 Overview
10.2 Cancer Vaccines Market Revenue Share, by End Use (2024 and 2031)
10.3 Pediatrics
- 10.3.1 Overview
- 10.3.2 Pediatrics: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
10.4 Adults
- 10.4.1 Overview
- 10.4.2 Adults: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

11. Cancer Vaccines Market Analysis And Forecasts To 2031 Geographical Analysis

11.1 North America: Cancer Vaccines Market
- 11.1.1 Overview
- 11.1.2 North America: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
- 11.1.3 North America: Cancer Vaccines Market, by Technology, 2024 and 2031 (USD Million)
- 11.1.4 North America: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
- 11.1.5 North America: Cancer Vaccines Market, by Indication, 2024 and 2031 (USD Million)
- 11.1.6 North America: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.1.7 North America: Cancer Vaccines Market, by Country, 2024 and 2031 (%)
- 11.1.8 US: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.1.8.1 US: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.1.8.2 US: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.1.8.3 US: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.1.8.4 US: Cancer Vaccines Market, by Technology2024 and 2031 (USD Million)
  - 11.1.8.5 US: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.1.9 Canada: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.1.9.1 Canada: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.1.9.2 Canada: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.1.9.3 Canada: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.1.9.4 Canada: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.1.9.5 Canada: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.1.10 Mexico: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.1.10.1 Mexico: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.1.10.2 Mexico: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.1.10.3 Mexico: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.1.10.4 Mexico: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.1.10.5 Mexico: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
11.2 Europe: Cancer Vaccines Market
- 11.2.1 Overview
- 11.2.2 Europe: Cancer Vaccines Market - Revenue and Forecast to 2031 (USD Million)
- 11.2.3 Europe: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
- 11.2.4 Europe: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
- 11.2.5 Europe: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
- 11.2.6 Europe: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.2.7 Europe: Cancer Vaccines Market, by Country, 2018 and 2031 (%)
- 11.2.8 Germany: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.8.1 Germany: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.8.2 Germany: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.2.8.3 Germany: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.2.8.4 Germany: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.2.8.5 Germany: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.2.9 UK: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.9.1 UK: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.9.2 UK: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.2.9.3 UK: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.2.9.4 UK: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.2.9.5 UK: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.2.10 France: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.10.1 France: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.10.2 France: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.2.10.3 France: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.2.10.4 France: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.2.10.5 France: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.2.11 Spain: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.11.1 Spain: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.11.2 Spain: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.2.11.3 Spain: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.2.11.4 Spain: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.2.11.5 Spain: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.2.12 Italy: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.12.1 Italy: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.2.12.2 Italy: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.2.12.3 Italy: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.2.12.4 Italy: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.2.12.5 Italy: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
11.3 Asia Pacific: Cancer Vaccines Market
- 11.3.1 Overview
- 11.3.2 Asia Pacific: Cancer Vaccines Market - Revenue and Forecast to 2031 (USD Million)
- 11.3.3 Asia Pacific: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
- 11.3.4 Asia Pacific: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
- 11.3.5 Asia Pacific: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
- 11.3.6 Asia Pacific: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.3.7 Asia Pacific: Cancer Vaccines Market, by Country, 2018 and 2031 (%)
- 11.3.8 China: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.8.1 China: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.8.2 China: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.3.8.3 China: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.3.8.4 China: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.3.8.5 China: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.3.9 Japan: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.9.1 Japan: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.9.2 Japan: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.3.9.3 Japan: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.3.9.4 Japan: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.3.9.5 Japan: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.3.10 India: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.10.1 India: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.10.2 India: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.3.10.3 India: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.3.10.4 India: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.3.10.5 India: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.3.11 South Korea: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.11.1 South Korea: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.11.2 South Korea: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.3.11.3 South Korea: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.3.11.4 South Korea: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.3.11.5 South Korea: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.3.12 Australia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.12.1 Australia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.3.12.2 Australia: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.3.12.3 Australia: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.3.12.4 Australia: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.3.12.5 Australia: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
11.4 Middle East and Africa: Cancer Vaccines Market
- 11.4.1 Overview
- 11.4.2 Middle East and Africa: Cancer Vaccines Market - Revenue and Forecast to 2031 (USD Million)
- 11.4.3 Middle East and Africa: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
- 11.4.4 Middle East and Africa: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
- 11.4.5 Middle East and Africa: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
- 11.4.6 Middle East and Africa: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.4.7 Middle East and Africa: Cancer Vaccines Market Share by Country and 2024 and 2031, (%)
- 11.4.8 Saudi Arabia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.4.8.1 Saudi Arabia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.4.8.2 Saudi Arabia: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.4.8.3 Saudi Arabia: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.4.8.4 Saudi Arabia: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.4.8.5 Saudi Arabia: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.4.9 UAE: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.4.9.1 UAE: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.4.9.2 UAE: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.4.9.3 UAE: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.4.9.4 UAE: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.4.9.5 UAE: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
- 11.4.10 South Africa: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  - 11.4.10.1 South Africa: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.4.10.2 South Africa: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
  - 11.4.10.3 South Africa: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
  - 11.4.10.4 South Africa: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
  - 11.4.10.5 South Africa: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
11.5 South and Central America: Cancer Vaccines Market
- 11.5.1 Overview
- 11.5.2 South and Central America: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
- 11.5.3 South and Central America Cancer Vaccines Market, by Type and Revenue and Forecast to 2031 (USD Million)
- 11.5.4 South and Central America Cancer Vaccines Market, by Indication and Revenue and Forecast to 2031 (USD Million)
- 11.5.5 South and Central America Cancer Vaccines Market, by Technology and Revenue and Forecast to 2031 (USD Million)
- 11.5.6 South and Central America Cancer Vaccines Market, by End User and Revenue and Forecast to 2031 (USD Million)
- 11.5.7 South and Central America: Cancer Vaccines Market, by Country, 2024 and 2031 (%)
- 11.5.8 Brazil: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.5.8.1 Brazil: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.5.8.2 Brazil Cancer Vaccines Market, by Type and Revenue and Forecast to 2031 (USD Million)
  - 11.5.8.3 Brazil Cancer Vaccines Market, by Indication and Revenue and Forecast to 2031 (USD Million)
  - 11.5.8.4 Brazil Cancer Vaccines Market, by Technology and Revenue and Forecast to 2031 (USD Million)
  - 11.5.8.5 Brazil Cancer Vaccines Market, by End User and Revenue and Forecast to 2031 (USD Million)
- 11.5.9 Argentina: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.5.9.1 Argentina: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
  - 11.5.9.2 Argentina Cancer Vaccines Market, by Type and Revenue and Forecast to 2031 (USD Million)
  - 11.5.9.3 Argentina Cancer Vaccines Market, by Indication and Revenue and Forecast to 2031 (USD Million)
  - 11.5.9.4 Argentina Cancer Vaccines Market, by Technology and Revenue and Forecast to 2031 (USD Million)
  - 11.5.9.5 Argentina Cancer Vaccines Market, by End User and Revenue and Forecast to 2031 (USD Million)

12. Impact Of COVID-19 Pandemic On Global Cancer Vaccines Market

12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Rest of World: Impact Assessment of COVID-19 Pandemic

13. Cancer Vaccines Market and Industry Landscape

13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
- 13.3.1 Overview
13.4 Inorganic Developments
- 13.4.1 Overview

14. Company Profiles

14.1 CSL Limited
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 ADURO BIOTECH INC.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Astellas Pharma Inc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Bristol-Myers Squibb Company
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 GlaxoSmithKline plc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Dendreon
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AstraZeneca
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Merck and Co., Inc.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Sanofi (Sanofi Pasteur)
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 OSE Immunotherapeutics
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms